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Unraveling the mysteries of protein folding and misfolding
Abstract
This mini-review focuses on the processes and consequences of protein folding and misfolding. The
latter process often leads to protein aggregation and precipitation with the aggregates adopting either
highly ordered (amyloid fibril) or disordered (amorphous) forms. In particular, the amyloid fibril is
discussed because this form has gained considerable notoriety due to its close links to a variety of
debilitating diseases including Alzheimer's, Parkinson's, Huntington's, and Creutzfeldt-Jakob diseases,
and type-II diabetes. In each of these diseases a different protein forms fibrils, yet the fibrils formed have
a very similar structure. The mechanism by which fibrils form, fibril structure, and the cytotoxicity
associated with fibril formation are discussed. The generic nature of amyloid fibril structure suggests that
a common target may be accessible to treat amyloid fibril-associated diseases. As such, the ability of
some molecules, for example, the small heat-shock family of molecular chaperone proteins, to inhibit
fibril formation is of interest due to their therapeutic potential.
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The dogma of protein folding, based largely on the work
of Christian Anfinsen some 50 years ago (1), is that all the
information required for a protein to fold into its proper
three-dimensional structure (and hence functional form) is
contained within its amino acid sequence. However, even
if, following translation, a protein successfully attains its
biologically active state, this often does not herald the
end-point of its folding/unfolding life. Many proteins go
through cycles of unfolding and refolding due to a variety
of factors that include transport across a membrane,
cellular secretion, or exposure to stress conditions (e.g.
changes in pH, temperature). As a result, the chance for
protein misfolding is relatively high and so the whole
process must be tightly regulated to ensure that it
functions smoothly. The failure of a protein to fold
correctly can have serious consequences; it is now
recognised that protein misfolding lies at the very heart of
a number of our most debilitating diseases (Table 1). This
review will focus on the process of protein misfolding,
highlighting its consequences (i.e. protein aggregation and
precipitation) and the forms that these misfolded protein
aggregates may take (ordered vs disordered). In
particular, the highly ordered protein aggregate known as
an amyloid fibril will be discussed since this form has
gained considerable notoriety due to its links to most of
the aforementioned diseases.
Proteins Can Aggregate Through Two Distinct
Mechanisms
During and immediately following its translation on the
ribosome, the newly formed protein meets the first major
hurdle of its life: to fold into the conformation it requires
in order to fulfil its raison d'etre. This, in itself, is not a
trivial task since the number of theoretical interactions
between each of its amino acid side chains far exceeds the
total number of protein molecules within the cell and
establishing the correct interactions is vital if the protein is
to fold correctly. In addition, the protein must fold within
the crowded environment of the cell, in which the
intracellular concentration of protein can be as high as 350
mg/mL (2), and so the chance of it making inappropriate
contacts with other proteins is very high. Yet, the driving
force that pushes the protein to attain its lowest free
energy state (i.e. its native conformation in the majority of
cases) ensures that most proteins fold spontaneously and
rapidly (in the order of micro- to milliseconds) and, more
often than not, folding occurs without problems (3).
Interestingly, some proteins never attain a defined
conformation, and instead, in their biologically active state,
remain intrinsically disordered, i.e. they have ill-defined
secondary and tertiary structures in their native state.
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For other proteins, folding does not occur unassisted and
instead the whole folding process is overseen by a
number of auxiliary proteins, such as catalysts and
molecular chaperones, which ensure a high degree of
folding fidelity. Whilst occurring quickly, the folding
pathway of a protein typically does not occur in one step
but instead proceeds through a number of intermediately
folded states (each with lower energy than the unfolded
protein) in which a few key initial contacts are established
that are crucial in directing the correct protein structure.
Subsequent hydrogen bonding and hydrophobic
interactions enable the protein to attain its fully folded
form (Fig. 1). The folding pathway is reversible. The
folded protein, when required to or when subjected to
stress (that causes the disruptions to hydrogen bonding
and hydrophobic interactions between some side chains),
partially unfolds to its intermediately folded state(s).
Table 1. Some known diseases associated with
amyloid fibril formation and the main protein
component of the aggregates formed.
Disease

Main protein

Alzheimer's disease

Aβ peptides, Tau

Frontal-temporal dementias

Tau

Parkinson's disease

α-Synuclein

Dementia with Lewy bodies

α-Synuclein

Transmissible spongiform
encephalopathies

Prion

Huntington's disease

Huntingtin

Type 2 diabetes

Amylin

Senile systemic amyloidosis

Transthyretin

Familial amyloid polyneuropathy I

Transthyretin

Familial amyloid polyneuropathy III

Apolipoprotein AI

Haemodialysis-related amyloidosis

β2-Microglobulin

Injection-localised amyloidosis

Insulin

Hereditary non-neuropathic systemic
amyloidosis

Lysozyme

Spinocerebellar ataxias

Ataxins

Spinocerebellar ataxia 17

TATA-box binding
protein

Primary systemic amyloidosis

Ig light chains

Secondary systemic amyloidosis

Serum amyloid A

Amyotrophic lateral sclerosis

Superoxide
dismutase I

Medullary carcinoma of the thyroid

Calcitonin
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Fig. 1. The protein on-folding pathway and the offfolding pathways that lead to protein aggregation. An
unfolded protein folds to its native state via the
formation of partially folded intermediates. This
process is fast and reversible. However, under
conditions in which the partially folded intermediates
persist (e.g. during times of cellular stress or due to
mutation), they can mutually associate via exposed
hydrophobic regions that are normally buried into the
core of the protein in its native state. When this
occurs, the intermediates aggregate via either a
disordered or ordered mechanism, leading to the
formation of amorphous precipitates or amyloid
fibrils, respectively.
Despite the number of checkpoints that exist to ensure
proper folding of proteins, problems can arise due to
undesirable interactions during folding. The main cause
of this is the persistence of intermediately folded states
of the protein on the folding pathway, a process that can
be exacerbated by mutation and/or cellular stress. These
intermediate states, which expose increased
hydrophobicity to solution, are prone to self-association,
leading to subsequent aggregation and precipitation.
When this occurs, the protein leaves the folding pathway
and enters the protein off-folding pathway, which is
relatively slow (in the order of seconds) and driven
primarily by the hydrophobic interactions between
intermediately folded states (Fig. 1). The off-folding
pathway comprises two distinct routes (into either
disordered or ordered aggregates) by which aggregation
of the protein may proceed. Determining which offfolding pathway predominates is often governed by the
speed at which protein unfolding and aggregation
occurs, its amino acid sequence and the nature of the
intermediates that are formed.
A disordered aggregation mechanism results from the
rapid unfolding and subsequent aggregation of
intermediately folded proteins, in which individual
monomers add to the growing clump of aggregated
protein through a random process. This leads to the
formation of amorphous aggregates which eventually
Vol 39 No 1 April 2008

become so large that they form an insoluble precipitate.
This type of aggregation is most often the bane of
protein researchers as it is the underlying mechanism
behind inclusion body formation in bacterial cells during
recombinant protein expression and is also responsible
for proteins 'falling out' of solution when changing
buffer conditions. With regards to inclusion body
formation, the huge amount of protein formed
overwhelms the cell's ability to properly fold the newly
expressed protein and so the misfolded protein
aggregates and precipitates. However, under normal
circumstances in the cell, amorphous aggregation is
often not of major concern since it is well equipped to
detect their formation and dispose of them into the
proteasomal 'dustbin' before they precipitate.
Amyloid Fibrils are Formed Through an Ordered
Aggregation Mechanism
In contrast to the formation of amorphous (disordered)
clumps of protein, aggregation may occur more slowly
through a highly ordered nucleation-dependent
mechanism in which partially folded forms of the
protein associate together to form a stable nucleus (the
rate determining step). This nucleus then acts as a
template to sequester other intermediates to add to the
growing thread of aggregated protein (protofibril). The
sequential addition of partially folded intermediates to
the ends of the chain leads to the formation of a highly
structured, insoluble form of protein known as an
amyloid fibril (Fig. 2A,B). Such a mechanism explains
the observed kinetics of fibril formation as monitored
using amyloid-binding dyes such as thioflavin T or
Congo red (Fig. 2C). Both the length of the lag phase
and the rate of elongation are highly dependent on the
protein concentration through their reliance on the
concentration of partially folded intermediates present at
any given time (4).
Amyloid fibril formation is often associated with
disease and is believed to be causative, or at least linked,
to disease onset and progression (5-7). However, the
disease related proteins found as fibrillar aggregates in
vivo share no obvious sequence or structural similarities
in their native state (Table 1). Moreover, the amyloid
fibril conformation has been found to be accessible to a
diverse range of proteins, such that it is now thought to
be a generic structural form that all proteins can adopt
given appropriate conditions (8).
The Generic Structure of Amyloid Fibrils
The characterisation of amyloid fibril formation by
proteins in vitro has, to date, largely focused on
biophysical studies to determine the structure of the
fibril, and biochemical studies into the mechanism and
kinetics of the process. Through such techniques as Xray fibre diffraction, cryo-electron microscopy and solid
state NMR spectroscopy we now have a detailed
understanding of the core architecture of individual
fibrils. All fibrils share a characteristic 'cross β-sheet
array', so called since individual fibrils are made up of
sheets of β-strands which lie perpendicular to the core
axis of the fibril and which stack together to form an
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Fig. 2. Monitoring the formation of amyloid fibrils and their generic
core architecture.
A. The typical structure of amyloid fibrils as viewed by transmission
electron microscopy, showing them as long, unbranched, rope-like fibres.
Scale bar is 1 µm.
B. In the left panel, a magnified view of a fibril highlighting its internal
protofilament substructure (scale bar is 200 nm). In the right panel, a
schematic view of an amyloid fibril formed from insulin. This model shows
the core structure of each filament, i.e. the typical cross β-sheet array formed
from sheets of β-strands lying perpendicular to the axis of the fibril and the
aligning of these β-sheets into individual filaments (reproduced from (26)).
C. Monitoring amyloid fibril formation via the change in fluorescence of
the amyloid-binding dye thioflavin T upon its binding to the fibril. The
kinetics of fibril formation include a lag phase, elongation phase and
plateau phase and the rate of fibril formation increases with increasing
concentrations of protein.
D. X-ray fibre diffraction of amyloid fibrils showing the diagnostic
meridional and equatorial reflections which form the 'cross β-sheet' pattern.
E. The nucleation-dependent model of amyloid fibril formation. Fibril
formation commences with the unfolding of a native protein, forming a
pool of partially folded intermediates, a process that is reversible. The
partially folded intermediates are able to associate with each other until
they reach a critical size/mass at which a stable nucleus is formed. The
formation of this nucleus from the partially folded intermediates is slow
and rate-limiting in the overall process of fibril formation (lag phase).
Fibril elongation then proceeds via the addition of intermediates to the
growing nucleus. The mechanism also explains how seeding the reaction
increases the reaction rate and decreases the lag phase since addition of
preformed fibrils overcomes the time required to form nuclei.
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individual filament (Fig. 2B). This results
in a characteristic cross formed by the
meridional (~ 4.7 Å) and equatorial (~ 911 Å) reflections in X-ray diffraction
studies (Fig. 2D), which represent the
hydrogen bonding distance between
adjacent β-strands that make up a β-sheet
and the distance between β-sheets,
respectively. The presence of this 'cross βsheet array' as the underlying architecture
of fibrils observed by techniques such as
transmission electron microscopy and
atomic force microscopy is now seen as
the diagnostic test for the presence of
amyloid fibrils. Mature fibrils are
commonly composed of two to six
protofilaments that plait together into
rope-like fibres, 5-10 nm in diameter and
up to a few microns in length. The fibrils
formed are often unbranched, extremely
stable and resistant to degradation by
proteases and denaturants. These
properties are thought to be responsible
for the difficulty the cell has in eliminating
fibrils once they have been formed.
The overall stability of the fibril is
achieved by intermolecular hydrogen
bonds involving backbone atoms between
the amide and carbonyl groups of the
polypeptide main chain; the peptide
backbone being common to all proteins is
therefore thought to dictate why all fibrils
share a common morphology. It also
explains why very structurally diverse
proteins are able to adopt the amyloidfibril conformation, including those which
are predominately α-helical in their native
state (9-11). However, the propensity for a
given peptide or protein to form fibrils
can vary dramatically with sequence and
some regions of a protein may be more
prone to aggregation than others. Thus,
whilst it may be true that all proteins are
capable of forming fibrils, the
composition and amino acid sequence of
a protein profoundly affects its propensity
to adopt such structures. Moreover, the
tendency of a polypeptide chain to
aggregate, rather than fold correctly,
depends on a number of intrinsic factors,
including the propensity for it to form βstrands, its hydrophobicity and its overall
net charge (12,13). The specific link
between these physiochemical properties
of constituent amino acid residues and
their aggregation propensities has led to
the development of a number of
predictive algorithms for amyloidogenic
regions of proteins that are based solely
on their amino acid sequences (14,15).
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Toxic Protein Aggregation and its Prevention
In each of the amyloid diseases, and there have now
been at least 20 which have been identified, the fibrils that
are formed are primarily associated with one protein or
protein fragment, e.g. the amyloid-β peptides Aβ1-40 and
Aβ1-42 in Alzheimer's disease, α-synuclein in Parkinson's
disease and the prion protein in the transmissible
spongiform encephalopathies (see Table 1). In many of
these diseases, the fibrils then self assemble into tangled
plaques, the hallmark of most neurodegenerative
conditions and the site at which the toxic effect of fibril
formation is most evident. However, the cytotoxicity
associated with amyloid formation is not restricted to
disease-related proteins; fibrils and their precursors
formed from non-disease related proteins, such as the
SH3 domain from bovine phosphatidylinositol 3' kinase
and the N-terminal domain of Escherichia coli HypF
protein (HypF-N), show similar levels of cytotoxocity (16).
There remains considerable debate as to the species
responsible for the cytotoxicity of amyloid fibrils.
Although there are obvious negative effects of
extracellular amyloid plaque deposition, recent studies
have suggested that it is primarily the soluble, prefibrillar dimers, trimers or other such oligomers, which
are formed during the early stages of fibril formation, that
are responsible for cell toxicity in neurodegenerative
diseases such as Alzheimer's and Parkinson's disease
(5,7). Others have indicated that the mature fibril can also
be toxic (17,18) and, in fact, the cytotoxic species may
vary depending on the precursor fibril-forming protein.
A wide variety of biochemical changes have been
reported following exposure of neuronal cells in culture
to amyloid fibrils or their precursors. It is not clear how
the species formed during amyloid fibril assembly cause
cell death, and indeed whether the mechanism behind the
toxicity is the same for all amyloid fibril-forming proteins.
A number of hypotheses have been proposed, for
example, that a soluble precursor forms a pore-like
structure in cell membranes (the amyloid channel or
amyloid pore) and this culminates in neuronal death by
unregulated membrane permeabilisation (19,20). Others
have suggested that the toxicity of prefibrillar amyloid
species is due to the production of reactive oxygen
species (e.g. hydrogen peroxide) by the aggregating target
protein itself, which are generated as a consequence of the
fibril-forming process (21). In support of this, cells can be
protected against amyloid aggregate toxicity by treatment
with antioxidants such as tocopherol, lipoic acid and
reduced glutathione. An advantage of some of these antioxidant compounds is that they also are able to inhibit the
process of fibril formation (22), most likely due to a direct
effect on the hydrophobic association steps required for
nuclei formation. Thus, these anti-oxidants or derivatives
thereof are promising drug targets due to their combined
anti-oxidant and anti-amyloidogenic activities.
Other well-described inhibitors of protein aggregation,
and therefore amyloid fibril formation, are molecular
chaperone proteins, in particular, intracellular small heat
shock proteins (sHsps) and extracellular clusterin (23).
The sHsps are a ubiquitous group of proteins that are the
first line of defence a cell has against physiological stress
Vol 39 No 1 April 2008

conditions that promote protein aggregation. The
chaperone action of sHsps does not require ATP
hydrolysis and therefore they can be utilised by the cell
under conditions in which energy levels are low, e.g.
during cellular stress. sHsps seem to employ two distinct
mechanisms to prevent protein aggregation. In some
instances, they bind to long-lived, partially structured
intermediates, primarily though hydrophobic interactions,
to form a stable, soluble, chaperone-target protein
complex (i.e. a 'reservoir of intermediates'). Neither sHsps
or clusterin have the capability of refolding the target
protein but instead act to maintain its solubility until
cellular conditions allow them to be picked up and acted
upon by other chaperones, such as Hsp70 and Hsp60, that
use ATP hydrolysis to refold the protein. In other cases,
sHsps may only transiently interact with the target to
stabilise it and allow it to refold back to its native state
upon release. We have found the latter to be the
mechanism utilised by the sHsp, α-crystallin, against fibril
formation by apolipoprotein C-II (24).
No matter which mechanism is utilised, sHsps and
clusterin are ideally suited to prevent amyloid fibril
formation since they act very efficiently against slowly
aggregating target proteins, a process that governs the
ordered aggregation mechanism that leads to fibril
formation. Interestingly, the expression of sHsps and
clusterin is upregulated in many amyloid
neurodegenerative diseases and they are found in high
amounts in amyloid plaques (25), presumably as a result
of their attempts to prevent protein aggregation. Studies
in which these chaperone proteins are overexpressed in
cellular models of amyloidoses will enable an assessment
of their therapeutic potential in the treatment of such
diseases.
Conclusions
Whilst often overlooked, the folding and unfolding process
faced by proteins during their life cycle is not a trivial one.
Like all biological processes, the folding pathway is tightly
regulated to ensure proteins reach their correct, functional
form. However, problems can occur and the number of
protein conformational diseases that are now recognised is an
indication of the importance of proteins achieving and
maintaining their correct fold. That the amyloid fibril
conformation is potentially accessible to all proteins, no
matter what their native state, indicates that for many this
form of toxic protein aggregation is a constant threat.
Significantly, diseases associated with amyloid fibril
formation represent some of the western world's most
debilitating conditions and, since many are associated with
old age, will become more prevalent over the coming
decades as the population ages. As such, a greater
understanding of the mechanism by which fibrils are formed
and strategies to prevent it are required.
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